Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Second Quarter of 2022

• Net sales of DARZALEX^® in the second quarter of 2022 totaled USD 1,986 million
• Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen)

COPENHAGEN, Denmark; July 19, 2022 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX^® (daratumumab), including sales of the subcutaneous (SC) formulation (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO^® in the U.S.), as reported by Johnson & Johnson were USD 1,986 million in the second quarter of 2022. Net trade sales were USD 1,021 million in the U.S. and USD 965 million in the rest of the world. Genmab receives royalties on the worldwide net sales of DARZALEX, both the intravenous and SC formulations, under the exclusive worldwide license to Janssen to develop, manufacture and commercialize daratumumab.

About Genmab
Genmab is an international biotechnology company with a core purpose to improve the lives of people with cancer. For more than 20 years, Genmab’s vision to transform cancer treatment has driven its passionate, innovative and collaborative teams to invent next-generation antibody technology platforms and leverage translational research and data sciences, fueling multiple differentiated cancer treatments that make an impact on people’s lives. To develop and deliver novel therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. Genmab’s proprietary pipeline includes bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates.

Genmab is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information, please visit Genmab.com and follow us on Twitter.com/Genmab.